Codupha Central Pharmaceutical JSC

Codupha Central Pharmaceutical JSC ROE

The Return on Equity (ROE) of Codupha Central Pharmaceutical JSC (CDP.VN) as of Oct 10, 2026 is 6.48 %. In the previous year, Return on Equity (ROE) was 3.32 % — a change of 95.27% (higher).

ROE

6.48 %

YoY

95.27%

Last updated:

In 2024, Codupha Central Pharmaceutical JSC's return on equity (ROE) was 6.48 %, a 95.27% increase from the 3.32 % ROE in the previous year.

The Codupha Central Pharmaceutical JSC ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2017
13.74 VND
Jan 1, 2018
11.88 VND
Jan 1, 2019
9.43 VND
Jan 1, 2020
6.26 VND
Jan 1, 2021
5.48 VND
Jan 1, 2022
9.37 VND
Jan 1, 2023
3.32 VND
Jan 1, 2024
6.48 VND
The Codupha Central Pharmaceutical JSC ROE history
YEARROEYoY
6.48 %+95.27%
3.32 %-64.58%
9.37 %+70.85%
5.48 %-12.44%
6.26 %-33.60%
9.43 %-20.60%
11.88 %-13.57%
13.74 %—
Access this data via the Eulerpool API
Get Free API Key

Codupha Central Pharmaceutical JSC Stock analysis

What does Codupha Central Pharmaceutical JSC do? Codupha Central Pharmaceutical JSC is one of the most popular companies on Eulerpool.

ROE Details

Decoding Codupha Central Pharmaceutical JSC's Return on Equity (ROE)

Codupha Central Pharmaceutical JSC's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Codupha Central Pharmaceutical JSC's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Codupha Central Pharmaceutical JSC's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Codupha Central Pharmaceutical JSC’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Codupha Central Pharmaceutical JSC stock

Return on Equity (ROE) of Codupha Central Pharmaceutical JSC is 6.48 % in 2024.

Return on Equity (ROE) of Codupha Central Pharmaceutical JSC changed from 3.32 % to 6.48 %, representing a 95.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Codupha Central Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Codupha Central Pharmaceutical JSC with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Codupha Central Pharmaceutical JSC

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Codupha Central Pharmaceutical JSC